Largest and first comprehensive Rheumatoid Arthritis Registry launched in Kuwait
- Kuwait: Thursday, December 20 - 2012 at 15:41
- PRESS RELEASE
In a scientific gathering of RA experts in Kuwait, the Kuwait Association of Rheumatology (KAR) has launched the biggest and first comprehensive Rheumatoid Arthritis (RA) Registry in Kuwait. On the sidelines of the announcement, a press conference was organized by Pfizer, one of the world's leading biopharmaceutical companies, to raise awareness about the RA gravity and the registry's advantage to patients with RA.
Rheumatoid Arthritis (RA) is a chronic disease that causes pain, sti¬ffness, swelling, and loss of function in the joints .
It causes inflammation that leads to swelling in the joints, making them progressively less and less mobile . If not managed properly, over time, RA can cause joint damage and even result in permanent joint destruction .
The RA Registry in Kuwait will include data about patients with RA for the period from 2012 to 2017. It will provide important insights about RA, available treatment options and assess the safety and efficacy of these treatments.
Six renowned hospitals from all over Kuwait have participated in the RA Registry - Al Amiri, Mubarak Al Kabeer, Farwania, Adan, Jahra, Sabah Hospital in addition to the Shaikhan Al Farisi Center - with an ultimate aim to offer a better care to patients with RA.
Dr Adel Al Awadhi said, "About 1% of the world's population is afflicted by rheumatoid arthritis . RA imposes significant social and economic burdens on the patients and country. If not treated effectively, patients would suffer from intense pain, become disabled and will need assistance in performing their daily activities; in addition to the cost that may occur due to their productivity loss and treatment expenses. We are delighted to launch the first RA Registry study in Kuwait as we believe it will generate vital datasets to showcase the patient's response to available RA therapies and hopefully to improve their care and treatment."
"It is necessary to constantly remind physicians about the importance of the RA early diagnosis. The early effective treatment of the disease may slow or even stop progression of joint damage . We hope that this biggest and first comprehensive RA Registry in Kuwait would be able to ultimately improve the RA patient care," said Dr Adeeba Abdullah Al Herz.
"Pfizer adheres to its values of quality, innovation and collaboration with the local Kuwaiti community by supporting this valuable research which will generate considerable data from patients with RA. The outcome will enrich the knowledge about this disabling disease which will shorten the patients suffer of treatments trials by enabling them to administer an effective and safe medication hence presume their normal daily life," said Yasser El Dershaby, Medical Director, Pfizer Gulf & Levant states.
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / 4C. AME Info FZ LLC / 4C is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.